Pharmacokinetic of inhaled low molecular weight heparin.

  title={Pharmacokinetic of inhaled low molecular weight heparin.},
  author={Gerhard Scheuch and Sabine Haeussermann and P. A. J. Brand and Christiane Herpich and Thomas Meyer},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  volume={24 18_suppl},
7209 Background: Treatment with Heparin and low molecular weight (LMW) Heparin is frequently used in oncology settings. Usually, these drugs are delivered by subcutaneous (s.c.) administration. Since 1963, the clinical relevance of inhalation of unfractionated as well as LMW-Heparin has been investigated in various studies with over 500 subjects. In this study, a single inhalation of the LMW-Heparin Certoparin (Mono-Embolex, Novartis) was investigated in 10 healthy subjects. The goal was to… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
0 Extracted Citations
0 Extracted References
Similar Papers

Similar Papers

Loading similar papers…